Intellectual Property India Publishes Patent Application for 'Prodrugs Of Topoisomerase I Inhibitor For Adc Conjugations And Methods Of Use Thereof' Filed by Regeneron Pharmaceuticals, Inc.

MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202517067595 A) filed by Regeneron Pharmaceuticals, Inc., Tarrytown, U.S.A., on July 15, for 'prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof.'

Inventor(s) include Han, Amy.

The application for the patent was published on July 25, under issue no. 30/2025.

According to the abstract released by the Intellectual Property India: "Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic moieties, e.g., camptothecin analogs and/or derivatives. In certain embodiments, provided are specific and efficient methods for producing protein-drug constructs (e.g., antibody-drug conjugates) utilizing a combination of transglutaminase and 1,3-cycloaddition techniques. Camptothecin analogs, antibody-drug conjugates, and compositions which comprise glutaminyl-modified antibodies and camptothecin analog payloads and are provided."

The patent application was internationally filed on Dec. 21, 2023, under International application No.PCT/US2023/085450.

Disclaimer: Curated by HT Syndication.